One of the biggest challenges for stem cell-based therapies in regenerative medicine is delivery and retention of stem cells at sites of tissue damage. Universally, less than 5% of delivered stem cells engraft in target tissues, which results in limited tissue regeneration and insufficient functional recovery. The majority of stem cells home to and accumulate at binding sites in the spleen. The same splenic accumulation has been documented for Car-T and NK treatment for cancer.
There is a tremendous clinical need for non-invasive biologic methods that enhance stem cell engraftment in target tissues. AVM0703, in addition to its general anti-inflammatory and lymphodepleting properties, is dosed to transiently reduce the size and number of stem cell binding niches in the secondary lymphatic system.
The proposed benefit of pre-treatment with AVM0703 prior to autologous stem cell administration is attracting high numbers of circulating stem cells into damaged tissue by reducing splenic stem cells sequestration. This action is expected to: